328,809 Shares in CeriBell (NASDAQ:CBLL) Purchased by Novo Holdings A S

Novo Holdings A S purchased a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 328,809 shares of the company's stock, valued at approximately $8,510,000. CeriBell accounts for about 0.5% of Novo Holdings A S's portfolio, making the stock its 26th biggest position. Novo Holdings A S owned approximately 0.92% of CeriBell as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Legal & General Group Plc purchased a new position in shares of CeriBell during the fourth quarter valued at about $32,000. Summit Investment Advisors Inc. bought a new position in CeriBell during the fourth quarter valued at approximately $33,000. Tower Research Capital LLC TRC bought a new stake in CeriBell in the 4th quarter worth approximately $37,000. PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the 4th quarter worth approximately $47,000. Finally, Corebridge Financial Inc. bought a new position in shares of CeriBell during the 4th quarter valued at approximately $158,000.

CeriBell Trading Up 0.2 %

Shares of CBLL traded up $0.04 during midday trading on Friday, hitting $16.32. The stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. The company's 50 day moving average is $18.85. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. Analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CBLL shares. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $32.50.

Insider Activity at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. The trade was a 0.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 24,700 shares of company stock worth $372,434 in the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.